论文部分内容阅读
目的 :探讨α-干扰素在肾癌根治术后的治疗作用。方法 :将 46例肾癌患者随机分成两组 ,治疗组 2 1例在肾癌根治术后应用α-干扰素治疗 ,对照组 2 5例单纯行肾癌根治术。结果 :治疗组 T淋巴细胞亚群 CD3和CD4/CD8比值较术前显著升高 (P <0 .0 5 ) ,接近正常对照 (P >0 .0 5 ) ,CD4阳性细胞显著性升高 (P <0 .0 5 ) ,CD8阳性细胞显著减少 (P<0 .0 5 ) ;对照组 CD3、CD4、CD8和 CD4/CD8比值与术前比较 ,差异均无显著性意义(P >0 .0 5 )。术后 3年 (90 .5 % )及 5年生存率 (89.5 % )明显高于对照组 (P <0 .0 5 )。结论 :肾癌根治术后应用α-干扰素治疗 ,有利于患者免疫功能恢复 ,增强机体抗肿瘤能力 ,消灭残留癌细胞 ,减少复发 ,提高生存率
Objective: To investigate the therapeutic effect of α-interferon after radical nephrectomy. Methods: Forty-six patients with renal cell carcinoma were randomly divided into two groups. In the treatment group, 21 patients were treated with interferon alpha after radical nephrectomy, and 25 patients in the control group were treated with radical nephrectomy alone. Results: The ratio of CD3 and CD4 / CD8 of T lymphocyte subsets in treatment group was significantly higher than that before operation (P <0.05), close to the normal control (P> 0.05), CD4 positive cells were significantly increased P <0. 05), the number of CD8 positive cells decreased significantly (P <0.05). There was no significant difference in the ratio of CD3, CD4, CD8 and CD4 / CD8 in the control group compared with that before operation (P> 0 5). Three years after operation (90.5%) and 5-year survival rate (89.5%) were significantly higher than those in the control group (P <0.05). Conclusion: The application of α-interferon after radical nephrectomy is beneficial to the recovery of immune function, enhancing the anti-tumor ability of the body, eliminating the residual cancer cells, reducing recurrence and increasing the survival rate